Q-omics provides the consensus-scored TRERNA1 profile across patient tissues and cancer cell-line models. TRERNA1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TRERNA1 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, TRERNA1 RNA expression shows 6,767 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, BRCA, and STAD as cancer lineages where TRERNA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRERNA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRERNA1 survival associations across molecular data types. TRERNA1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRERNA1 RNA expression–survival associations across cancer types. High TRERNA1 expression shows unfavorable associations in KIRP, OV, LGG, LAML, CESC and THCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TRERNA1 RNA expression.
This table summarizes TRERNA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRERNA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRERNA1 shows lower tumor expression in THCA, KICH and HNSC and higher tumor expression in BRCA and COAD. The BRCA box plot shows higher TRERNA1 RNA expression in tumor versus normal tissue (log2 FC = +0.048, t-test p = .011).
This table shows molecular features associated with TRERNA1 in patient tissues and cancer cell lines. In patient samples, TRERNA1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
